Paluch-Shimon et al. studied 137 metastatic HER2+ BC patients and similarly showed that compared to HR− (n = 81) patients, HR+ patients (n = 56) had a trend for more bone metastasis (49% vs. 34%, p = 0.10) [14]. The gene discussed is ERBB2; the disease is breast cancer.